Pyridazinone compounds and their use as daao inhibitors

A compound of formula (I)

• wherein
• R1 is chosen from a hydrogen or fluorine atom or a trifluoromethyl group;
• R2 represents a group —X—Y—R3;
• X and Y each independently are chosen from a bond, an oxygen atom, or a group —C(O), —S(O)n, —C(O)NR4, —S(O)2NR4, —NR4,
• or —CR4R5—, with the proviso that X and Y cannot both simultaneously represent a bond, and if X and Y are both not a bond, then at least one of X and Y represents —CR4R5—;
• n is chosen from 0, 1 or 2;
• each R4 independently is chosen from a hydrogen atom or a C1-C6 alkyl or C1-C6 haloalkyl group;
• each R5 independently is chosen from a hydrogen atom, a C1-C6 alkyl or C1-C6 haloalkyl group or ═CH—;
• R3 is chosen from a 3- to 10-membered saturated or unsaturated carbocyclic or heterocyclic ring system, wherein the ring system is unsubstituted or substituted by at least one substituent chosen from halogen, hydroxyl, cyano, oxo, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6 alkylsulphinyl, C1-C6 alkylsulphonyl, C1-C6 alkylcarbonyl, C1-C6 alkylcarbonyloxy, C1-C6 alkoxycarbonyl, amino (—NH2), —CON(R6)2, C1-C6 alkylamino, di-(C1-C6 alkyl)amino, C3-C6 cycloalkyl, C3-C6 cycloalkyloxy, C3-C6 cycloalkylmethyl, —[O]p—(CH2)q—O—R7 or a 4- to 6-membered saturated or unsaturated heterocyclic ring, which is unsubstituted or substituted with at least one substituent chosen from C1-C4 alkyl or C1-C4 alkoxy;
• each R6 independently is chosen from a hydrogen atom or a C1-C6 alkyl group;
• p is chosen from 0 or 1;
• q is chosen from 1, 2, 3 or 4;
• and
• R7 is chosen from a C1-C6 alkyl group;
• or a pharmaceutically acceptable salt thereof.